By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Similar Posts
Early Alert: Infusion Pump Software Issue from Baxter
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramCDER SBIA On-Demand Learning Library
FDA’s CDER Small Business and Industry Assistance (SBIA) is making available our YouTube learning library – now hundreds of our recordings are readily accessible.Kabana Skin Care LLC – 710232 – 07/18/2025
CGMP/Finished Pharmaceuticals/AdulteratedFukuzyu Pharmaceutical Co., Ltd. – 1/19/2024
Fukuzyu Pharmaceutical Co., Ltd. – 1/19/2024. Country: Japan. Record Type: 483Ongoing | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.Gina Marie Bakery of Waterbury Issues Recall of Cookies Due to Undeclared Almonds, Sesame and Food Dyes
Gina Marie Bakery of Waterbury, CT is recalling 1lb and 2 lb packages of the above-mentioned cookies because they contain undeclared allergens. People who have allergies to nuts, sesame seeds and/or food dyes run the risk of serious or life-threatening allergic reaction if they consume these produc
